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DOI 10.1016/j.ccr.2010.05.023SUMMARYPIK3CA andPTEN alterations are common in human cancer, but only a fraction of such tumors are dependent
upon AKT signaling. AKT independence is associated with redundant activation of cap-dependent transla-
tion mediated by convergent regulation of the translational repressor 4E-BP1 by the AKT and ERK pathways.
This provides mechanistic bases for the limited activity of AKT andMEK inhibitors in tumors with comutation
of both pathways and the profound synergy observed with combined inhibition. Whereas such tumors are
sensitive to a dominant active 4E-BP1 mutant, knockdown of 4E-BP1 expression reduces their dependence
on AKT/ERK signaling for translation or survival. Thus, 4E-BP1 plays a prominent role in mediating the effects
of these pathways in tumors in which they are activated by mutation.INTRODUCTION
Mutational activation of mitogenic signaling is a frequent event in
human cancer. Mutations in genes that encode components of
the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways occur
at high frequency in cancer and often coexist (McCubrey et al.,
2007; Shaw and Cantley, 2006). The former pathway is activated
in a majority of human cancers, due to mutations in PIK3CA,
which encodes the catalytic subunit of PI3 kinase p110a, inacti-
vation or decreased function of PTEN, or activation of receptor
tyrosine kinases (Samuels et al., 2004; Vivanco and Sawyers,
2002). Activation of the PI3K pathway causes changes in metab-
olism, transcription, protein translation, and other processes that
contribute to the transformed phenotype.Significance
In tumors with coexistentmutational activation of PI3K/AKT and
formation, whereas deletion of either causes the tumor to becom
mutation abrogates addiction of the tumor to the first by causin
both pathways. 4E-BP1 is a key integrator of these pathway
a potential target for therapy. We find that combined inhibitio
4E-BP1 phosphorylation and tumor growth. This is, therefore
both pathways are activated.The concurrent activation of the PI3K/AKT and ERK pathways
by separate mutations occurs in a significant portion of human
tumors (Liu et al., 2008; Simi et al., 2008; Tsao et al., 2004).
The selective advantage of activating both pathways is unknown
but has been thought to be due to distinct effects of each that are
necessary for tumor growth. However, we and others have found
that, in such tumors, inhibiting either pathway alone has negli-
gible effects on tumor growth and survival (Hoeflich et al.,
2009; She et al., 2005; Wee et al., 2009; Yu et al., 2008). One
possible explanation is that these pathways activate a common
set of downstream targets. If so, inhibition of neither pathway
alone would be sufficient to inactivate these targets. They would
thus serve to integrate the biologic effects of both pathways on
transformation.ERKpathways, inhibition of both is required to inhibit trans-
e dependent on the other. The data suggest that the second
g redundant activation of targets that integrate the effects of
s that mediates their effects on transformation and is thus
n of AKT and MEK is feasible in vivo and effectively inhibits
, a therapeutic strategy for the many malignancies in which
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Figure 1. Tumor Cells with Coexistent RAS
or RAF Mutations Are Resistant to AKT
Inhibition
(A) Cell growth was assessed by using the Cell-
Titer-Glo luminescent cell viability assay after
3 days of treatment with AKTi (0–10 mM). The
results are expressed as half-maximal growth
inhibitory concentration (IC50) of AKTi.
(B) Cells were treated with 1 mM AKTi, and the cell
lysates were immunoblotted with the indicated
antibodies. See also Figure S1.
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4E-BP1 Integrates AKT and ERK FunctionIn this study, we tested this hypothesis and investigated
the consequences and therapeutic implications of coexistent
mutational activation of PI3K/AKT and RAS/ERK signaling in
carcinomas.
RESULTS
Coexistent Mutational Activation of ERK Signaling
in Tumors Is Associated with AKT Independence
Weusedan allosteric inhibitor of AKT (AKTi) to interrogate apanel
of tumor cell lines with PIK3CA or PTENmutation and determine
their dependence on the pathway. AKTi is a non-ATP-competi-
tive, PH-domain-dependent inhibitor of AKT1 (EC50 3.5 nM)
and AKT2 (EC50 42 nM) with less potency against AKT3 (EC50














sselective, with no inhibition of other AGC
kinases. AKTi inhibited AKT phosphoryla-
tion and downstream signaling in tissue
culture and in vivo (She et al., 2008 and
Figure S1A available online).
We have used this compound to show
that breast cancer cells with PI3K muta-
tion or HER2 amplification are selectively
dependent on AKT signaling compared to
those in which the pathway is not acti-
vated (She et al., 2008). However, not all
tumor cells with PI3K or PTEN mutation
are sensitive to the AKTi (Figure 1A and
Figure S1B). PI3K or PTENmutation often
coexists with RAS or BRAF mutation
(Simi et al., 2008; Tsao et al., 2004) or hy-
peractivation of EGFR (Mellinghoff et al.,
2005; She et al., 2005). Analysis of this
panel of cell lines showed that a sig-
nificant fraction had coexistent PIK3CA
and KRAS or BRAF mutations or coexis-
tent PTEN loss and BRAF mutations
(Table S1). All cells with coexistent
KRAS or BRAF mutation were resistant
to AKT inhibition. Ten tumor cell lines in
the panel were sensitive to the drug;
none of these harbored KRAS or BRAF
mutation.
The effects of the AKTi were compared
in sensitive tumor cells with PIK3CA
mutation (e.g., BT474, breast cancer)nd insensitive tumor cells with coexistent KRAS and PIK3CA
utations (e.g., HCT116, colorectal) (Figure 1B). Unlike ATP-
ompetitive AKT inhibitors, the AKTi prevents the phosphoryla-
on of AKT by preventing its association with the membrane
herrin et al., 2010). In all of these cell lines, 1 mM AKTi inhibited
KT phosphorylation and phosphorylation of AKT substrates
oxo1 and Foxo3a. In BT474, the phosphorylation of down-
tream targets of AKT signaling, p70S6K, S6, and 4E-BP1, as
ell as the expression of cyclin D1 were also inhibited. This is
pical of tumor cell lines that are sensitive to AKT inhibition,
cluding the three other PIK3CA mutant (T47D, MCF7, MDA-
53) and two PTEN mutant (ZR-75-1, LNCaP) tumor cell
nes (She et al., 2008). In contrast, in HCT116, neither p70S6K,
6, or 4E-BP1 phosphorylation nor cyclin D expression was
uppressed, despite effective inhibition of AKT and Foxo
Figure 2. Tumor Cells with Coexistent PIK3CA and KRAS Mutations Are Sensitive to Combined Inhibition of AKT and KRAS/MEK/ERK
Signaling
(A) The growth of HCT116 cells was assessed after 3 days of treatment with PD0325901 (PD901) alone or in combination with AKTi. The results are expressed as
the cell numbers relative to those with the DMSO-treated controls. Values represent means ± SEM (n = 3).
(B) The growth of HCT116 cells were analyzed after 3 days of treatment with the drug combinations. Combination index (CI) values were determined by using the
method of Chou and Talalay, (1984) (CompuSyn software) for drug combinations with a fractional effect between 0.2 and 0.9 (20%–90% of cell growth inhibition
relative to control). CI values <1 indicate drug synergy.
(C) HCT116 cells were treated with AKTi or DMSOwith or without PD0325901 for 72 hr. Apoptosis was assessed by sub-G1 fraction of the cells. Values represent
means ± SEM (n = 3).
(D) siRNAs against KRAS, control nontargeting siRNAs, or transfection reagents (Mock) were transfected into HCT116 cells and incubated for 48 and 72 hr.
Cell lysates were immunoblotted with the indicated antibodies.
(E) siRNAs against KRAS or control siRNAs were transfected into HCT116 cells and incubated for 48 hr. The cells were then treated with 50 nM PD0325901 and
1 mMAKTi, alone or in combination or DMSO for the indicated additional times. Apoptosis was assessed by sub-G1 fraction of the cells. Values represent means
± SEM (n = 3). See also Figure S2.
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4E-BP1 Integrates AKT and ERK Functionphosphorylation (Figure 1B). Similar results were obtained in
other tumor cells (DLD1, HCT15, and T84) with concurrent
PIK3CA and KRAS mutations (Figures S3A, S5 and data not
shown). The survival and proliferation of these cells were affected
only marginally by AKT inhibition (Figures 1A, 2A, and 2C and
Figure S1B). Thus, the phosphorylation of Foxo and other prox-
imal targets of AKT are suppressed by the AKTi in all cells tested,
whether or not their growth is AKT dependent. In contrast, phos-
phorylation of regulators of cap-dependent translation (p70S6K,
S6, 4E-BP1) and expression of cyclin D1 are suppressed by the
AKTi only in tumor cells whose growth is sensitive to the drug.
Combined Inhibition of AKT and ERK Signaling Causes
Growth Arrest and Apoptosis in Tumors with Coexistent
Pathway Activation
The results suggest that coexistent KRAS mutation may cause
tumor cells to become AKT independent. The MEK/ERK kinases
are key downstream effectors of RAS signaling (McCubrey et al.,
2007). A selective inhibitor of MEK (PD0325901) had only a
marginal effect on growth in tumor cells with coexistent KRAS
and PIK3CA mutations (HCT116, DLD-1, HCT15, T84, H460)
(Figure 2A and Figure S2A). However, combined inhibition ofMEK and AKT caused synergistic inhibition of proliferation and
induction of apoptosis (Figures 2A–2C and Figure S2B). More-
over, inhibition of KRAS expression with small interfering RNA
in tumor cells with coexistent KRAS and PIK3CA mutations
had no effect on the survival of HCT116, but combined inhibition
of KRAS expression and AKT activity induced apoptosis syner-
gistically (Figures 2D and 2E). MEK inhibition did not increase
the apoptosis induced by KRAS knockdown in combination
with AKT inhibition (Figure 2E).
Thus, tumors inwhichKRAS/MEK/ERKandPI3K/AKTsignaling
are dysregulated by mutation are dependent on neither pathway
alone, but are sensitive to combined inhibition of both. If each
pathway activated distinct processes necessary for tumor cell
proliferation, the tumor would be suppressed by inhibiting either.
The requirement for combined inhibition suggests that the two
pathways activate converging targets that integrate their function.
AKT or ERK Signaling Is Sufficient to Support
Cap-Dependent Translation in Tumors with Coexistent
Pathway Activation
In breast tumor cells with PI3K/AKT activation, phosphorylation
of p70S6K, S6, and 4E-BP1 were downregulated by the AKTCancer Cell 18, 39–51, July 13, 2010 ª2010 Elsevier Inc. 41
Figure 3. Combined Inhibition of AKT and MEK Is Required for Effective Inhibition of Cap-Dependent Translation in Tumor Cells with
Coexistent PIK3CA and KRAS Mutations
(A, B, D, and E) T47D (A and B) and HCT116 (D and E) cells were treated with 50 nM PD0325901 and 1 mM AKTi, alone or in combination for 6 hr (A and B) or the
indicated times (D and E). Cell lysates were immunoblotted with the indicated antibodies (A and D) or precipitated with m7GTP sepharose beads followed by
immunoblotting of 4E-BP1 and eIF4E (B and E).
(C and F) T47D (C) and HCT116 (F) cells were transfected with a bicistronic luciferase reporter plasmid that detects cap-dependent translation of theRenilla lucif-
erase gene and cap-independent Polio IRES-mediated translation of the firefly luciferase gene. The transfected cells were treated with 50 nM PD0325901 and
1 mM AKTi, alone or in combination. Luciferase activities were measured by a dual-luciferase assay, and the Renilla/firefly luciferase luminescence ratio was
calculated for cap-dependent translational activity. The results are expressed as the inhibition of cap-dependent translation relative to theDMSO-treated controls
at each time and presented as means ± SEM (n = 3).
(G and H) HCT116 cells were treated with 50 nM PD0325901 and 1 mM AKTi, alone or in combination or DMSO for 12 hr (G) or the indicated times (H). The cell
lysates were separated on sucrose gradients (10%–50%) and fractionated to visualize the indicated ribosomal species. The absorbance of translated polysomes
(P) and untranslated monosomes (M) was continuously monitored at 254 nm, and the vertical dashed line separates the polysomal and monosomal fractions.
The P/M ratio, an index of translational efficiency, was calculated by comparing areas under the polysome and monosome peaks using NIH image J. The results
are expressed as a percentage of the P/M ratio relative to the DMSO-treated controls at each time and presented as means ± SEM (n = 2) (H).
(I) 35S-methionine incorporation into protein was determined for HCT116 cells that were treated with 50 nMPD0325901 and 1 mMAKTi, alone or in combination or
DMSO for 12 hr. The results are expressed as a percentage of 35S-methionine incorporation/mg protein relative to the DMSO-treated controls and presented as
means ± SEM (n = 2). See also Figure S3.
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4E-BP1 Integrates AKT and ERK Functioninhibitor but not by MEK inhibition (Figures 1B and 3A). Dephos-
phorylation of 4E-BP1 allows it to bind to the eIF4E-mRNA cap
complex and prevents cap-dependent translation (Richter and
Sonenberg, 2005). In PIK3CA mutant, KRAS/BRAF wild-type
cancer cells, inhibition of AKT, but not MEK, caused recruitment
of 4E-BP1 to the mRNA cap complex and inhibited cap-depen-
dent translation (Figures 3B and 3C). In contrast, in tumor cells
with coexistent KRAS and PIK3CA mutations (HCT116), inhibi-42 Cancer Cell 18, 39–51, July 13, 2010 ª2010 Elsevier Inc.tion of neither AKT nor MEK was sufficient to rapidly inhibit
phosphorylation of p70S6K, S6, or 4E-BP1 at any of its four
phosphorylation sites, although modest inhibition was observed
after exposure to theMEK inhibitor for 24 hr. However, combined
inhibition of MEK and AKT synergistically inhibited phosphoryla-
tion of all these sites 6 hr after drug exposure and profoundly by
12 hr (Figure 3D). This was associated with synergistic induction
of 4E-BP1 binding to the eIF4E-mRNA cap complex within 3 hr
Cancer Cell
4E-BP1 Integrates AKT and ERK Functionafter drug addition and increasing up to 12 hr after treatment
(Figure 3E). Inhibition of AKT or MEK kinase alone had little effect
at earlier time points, but each caused some 4E-BP1 recruitment
12 hr after pathway inhibition. Similar results were observed
in T84 cells with coexistent KRAS and PIK3CA mutations
(Figure S3A). The degree of recruitment of 4E-BP1 to the cap-
complex correlated with extent of inhibition of cap-dependent
translation (Figure 3F). MEK or AKT inhibition alone had modest
inhibitory effects on translation (5%–7%) 12 hr after drug addi-
tion, whereas combined inhibition caused 17% inhibition. The
effects of combined knockdown of AKT1 and AKT2 expression
on cap-dependent translation were very similar to those of the
AKT inhibitor (Figures S3B and S3C).
Actively translated mRNA is found in polysomes and changes
in overall translational efficiency are reflected by changes in the
polysome/monosome (P/M) ratio. The effects of MEK and AKT
inhibition, alone or in combination, on P/M ratio were determined
in HCT116. Figure 3G shows a representative sucrose gradient
from cells treated with drug for 12 hr. Inhibition of MEK or AKT
kinase alone had minor effect on the P/M ratio at 6 hr, although
some reduction (25%–29%) was observed 12 hr after exposure
to each drug (Figure 3H). Combined inhibition synergistically
reduced the P/M ratio (39%) 6 hr after drug addition and pro-
foundly (60%) by 12 hr. Combination treatment resulted in
more marked suppression of total protein synthesis (55%) than
either agent alone (17%–25%) (Figure 3I). Inhibition of translation
was associated with loss of expression of multiple regulators of
growth and survival, including D-cyclins and survivin (Figure 6A
and Figure S5 and data not shown).
Thus, tumors with PI3K mutation that are wild-type for RAS
and BRAF depend upon AKT signaling for phosphorylation of
various regulators of translation, including 4E-BP1, assembly
of active preinitiation translation complexes, maintenance of
high levels of translation, and cell growth and survival. In con-
trast, in tumors with coexistent RAS mutation, inhibition of AKT
has onlyminor effects on these processes. In such tumors, either
AKT or MEK/ERK signaling is sufficient to support translation,
and inhibition of both pathways is necessary for its significant
suppression.
To determine if KRAS mutation is responsible for loss of AKT
dependence in these cells, we compared parental HCT116 and
DLD-1 cells with isogenic derivatives in which the mutant
KRAS allele was deleted (Shirasawa et al., 1993). The deletion
of the mutant KRAS allele was sufficient to confer AKT depen-
dence to these PIK3CA mutant cells (Figure 4A). Unlike the
parental HCT116, inhibition of AKT alone in HKh-2 and HKe-3
(wild-type RAS) cells was sufficient to inhibit phosphorylation
of p70S6K, S6, and 4E-BP1, induce binding of 4E-BP1 to the
eIF4E-mRNA complex, and inhibit cap-dependent translation
(Figures 4B and 4C and Figure S4). 4E-BP1 binding to the com-
plex and inhibition of translation were not induced further in
these cells by MEK inhibition. Conversely, deletion of the endog-
enous mutant PIK3CA allele in HCT116 or DLD-1 cells (Samuels
et al., 2005) had the opposite effect: sensitization of these
processes and cell growth and survival to MEK inhibition (Fig-
ures 4D–4F).
Thus, dysregulation of ERK by RAS mutation is responsible
for the loss of AKT dependence of translation. MAP kinase-
interacting kinases (MNKs) are activated by ERK signaling andmay regulate translation via phosphorylation of eIF4E (Buxade
et al., 2008). Knockdown of MNK1/2 did inhibit eIF4E phosphor-
ylation but had no effects on phosphorylation of p70S6K, S6,
and 4E-BP1, induction of 4E-BP1 binding to the eIF4E, or cap-
dependent translation, nor did it enhance the effect of the
AKTi on these processes (Figures S3D and S3E). In this system,
therefore, the ERK effect on translation is not mediated by
MNK1/2.4E-BP1 Integrates the Effects of AKT and ERK Signaling
on Translation and Survival
Thus, tumors with coexistent mutations depend on neither
pathway alone but are sensitive to combined inhibition of both.
This implies that there are downstream targets that are regulated
by both activated pathways, so that inhibition of neither alone
is effective. These targets may include components of the net-
works that regulate apoptosis such as BAD (She et al., 2005)
and, as shown here, cap-dependent translation (p70S6K, S6,
4E-BP1).
Combined inhibition of AKT and MEK kinase caused the
recruitment of both 4E-BP1 and 4E-BP2 to the eIF4E-mRNA
cap complex (Figure 5A). Reduction of 4E-BP1 expression with
siRNA knockdown markedly reduced the dependence of trans-
lation on AKT and ERK signaling (Figures 5B and 5C). Combined
inhibition caused 23% inhibition of cap-dependent translation in
control cells but had onlyminimal effects in cells in which 4E-BP1
expression was suppressed (Figure 5C). Decreased 4E-BP2
expression had much less marked effects, and combined inhibi-
tion of 4E-BP1 and 4E-BP2 was not much more effective than
4E-BP1 loss alone (Figures 5B and 5C). The results suggest
that phosphorylation of 4E-BP1 is themajor effector of activation
of cap-dependent translation by AKT andMEK signaling in these
tumors.
Phosphorylation of 70S6K and ribosomal protein S6 are also
downstream of PI3K/AKT and MEK/ERK signaling and sensitive
to their combined inhibition (Figures 3 and 4). Knockdown of
p70S6K1 or S6 did modestly attenuate the effects of combined
inhibition of AKT and ERK on translation, but to a much lesser
degree than knockdown of 4E-BP1 (Figures 5B and 5C). Further-
more, knockdown of 4E-BP2, p70S6K, or S6 in combination with
4E-BP1 knockdown did not further enhance the effects of the
latter (Figure 5C).
The importance of 4E-BP1 dephosphorylation and binding to
eIF4E in mediating the effects of combined AKT and MEK path-
way inhibition was confirmed in HCT116 cells in which eIF4E
protein was exogenously overexpressed (Figure 5D). In these
cells, the effect of combined inhibition of MEK and AKT on cap-
dependent translation was significantly reduced (Figure 5E).
These data suggest that 4E-BP1 is the key integrator of the
effects of ERK and PI3K/AKT activation on cap-dependent
translation in tumor cells.
Disabling the inhibitory effects of 4E-BP1 by phosphorylation
may exert important biologic effects in transformed cells. Down-
regulation of 4E-BP1 expression with siRNA significantly attenu-
ated the apoptotic response associated with inhibition of MEK
and AKT (Figure 5F). Thus, the suppression of apoptosis by
mutant RAS and PI3K is mediated, in part, by phosphorylation
of 4E-BP1.Cancer Cell 18, 39–51, July 13, 2010 ª2010 Elsevier Inc. 43
Figure 4. Deletion of Mutant KRAS or PIK3CA Confers Dependence on the Other Pathway in Tumors in Which These Mutations Coexist
(A) The growth of isogenic HCT116 andDLD-1 cell lines in which themutant allele ofKRASwas deleted by homologous recombination were assessed after 3 days
culture in the presence of AKTi. The results are expressed as IC50 of AKTi. Values represent means ± SEM (n = 3).
(B and D) Cells were treatedwith 50 nMPD0325901 and 1 mMAKTi, alone or in combination for 6 hr. Cell lysateswere immunoblottedwith the indicated antibodies
or precipitated with m7GTP sepharose beads followed by immunoblotting of 4E-BP1 and eIF4E.
(C) Cells were transfected with a bicistronic luciferase reporter plasmid and then treated with 50 nM PD0325901 and 1 mM AKTi, alone or in combination.
The inhibition of cap-dependent translation was determined as in Figure 3C. Values represent means ± SEM (n = 3).
(E) The growth of HCT116 and DLD-1 isogenic cell lines in which the mutant allele of PIK3CA was deleted by homologous recombination were assessed after
3 days culture in the presence of PD0325901. The results are expressed as IC50 of PD0325901. Values represent means ± SEM (n = 3).
(F) Cells were treated with DMSO or the indicated concentration of PD0325901 for 72 hr. Apoptosis was assessed by sub-G1 fraction of the cells. Values repre-
sent means ± SEM (n = 2). See also Figure S4.
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4E-BP1 Integrates AKT and ERK FunctionCombined Inhibition of AKT and ERK Is Required
to Suppress 4E-BP1 Phosphorylation and Tumor Growth
In Vivo
These data suggest that inhibition of both pathways may be
required to significantly affect human tumors with concurrent
mutation of KRAS and PIK3CA. To explore the feasibility of this
therapeutic strategy, we tested the safety and efficacy of inhibit-
ing MEK and AKT in tumor xenografts with this genotype. As we
have previously shown, AKTi 100 mg/kg and the MEK inhibitor
PD0325901 5 mg/kg effectively inhibit the phosphorylation of
AKT or ERK, respectively, in PIK3CA or RAS mutant xenografts
(She et al., 2008; Solit et al., 2006). After four consecutive daily
treatments, phosphorylation of AKT was profoundly inhibited
by the AKTi and phosphorylation of ERK was inhibited by44 Cancer Cell 18, 39–51, July 13, 2010 ª2010 Elsevier Inc.PD0325901 by 5 hr after the last dose and inhibition of both path-
ways persisted for at least 24 hr (Figure 6A). Neither drug alone
caused effective inhibition of p-S6, p-4E-BP1, or D-cyclin levels
nor did they induce PARP cleavage in models with concurrent
mutations of both KRAS and PIK3CA. Inhibition of both path-
ways, however, did induce these effects synergistically. Similar
results were obtained after treatment with the drugs for 4 weeks
(Figure S5). These results confirm the relevance of the tissue
culture data to in vivo models.
Chronic administration of both drugs together on a Monday
through Friday schedule was well tolerated without weight loss
in the animals (data not shown). In four tested models, the
AKTi or MEK inhibitor had only marginal or modest antitumor
effects (Figures 6B–6E). Neither drug alone completely inhibited
Figure 5. 4E-BP1 Mediates the Effects of AKT and MEK Activation on Cap-Dependent Translation and Survival
(A) HCT116 cells were treatedwith 50 nMPD0325901 and 1 mMAKTi, alone or in combination for 6 hr. Cell lysates were precipitatedwithm7GTP sepharose beads
followed by immunoblotting with the indicated antibodies.
(B) siRNAs against the indicated genes or control siRNAs were transfected into HCT116 cells and incubated for 72 hr. Cell lysates were immunoblotted with the
indicated antibodies.
(C) siRNAs against the indicated genes or control siRNAs were transfected into HCT116 cells and incubated for 30 hr. The cells were then transfected with
a bicistronic luciferase reporter plasmid for 24 hr and then treated with 50 nM PD0325901 and 1 mM AKTi, alone or in combination for an additional 12 hr.
The inhibition of cap-dependent translation was determined as in Figure 3C. Values represent means ± SEM (n = 3).
(D) Detection of eIF4E and b-actin by immunoblot in HCT116 cells expressing the indicated transgenes.
(E) HCT116 cells expressing eIF4E or control vector were transfected with a bicistronic luciferase reporter plasmid for 24 hr and then treated with 50 nM
PD0325901 and 1 mM AKTi, alone or in combination for an additional 12 hr. The inhibition of cap-dependent translation was determined as in Figure 3C. Values
represent means ± SEM (n = 3).
(F) siRNAs against 4E-BP1 or control siRNAs were transfected into HCT116 cells and incubated for 48 hr. The cells were then treated with 50 nM PD0325901 and
1 mM AKTi, alone or in combination for the indicated additional times. Apoptosis was assessed by sub-G1 fraction of the cells. The results are expressed as the
increased levels of apoptosis by subtracting each of the DMSO-treated controls and presented as means ± SEM (n = 3).
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4E-BP1 Integrates AKT and ERK Functiontumor growth. However, AKTi in combination with PD0325901
synergistically suppressed growth in all four models with tumor
regression observed in HCT116 and T84 (p < 0.01 for combina-
tion of AKTi and PD0325901 versus AKTi, PD032901, or control).
Our data imply that dephosphorylation of 4E-BP1 alone should
significantly inhibit tumor growth. To test this assertion, we used
a mutant 4E-BP1 (4Ala) in which its four known phosphorylation
sites (Thr 37, Thr46, Ser65, Thr70) were replaced with alanine.
This mutant 4E-BP1 cannot be phosphorylated and binds
constitutively to eIF4E (Rong et al., 2008 and Figure 7A). As
compared to wild-type 4E-BP1 and vector control, expressionof 4E-BP1 (4Ala) effectively suppressed tumor growth in vivo
(Figures 7B and 7C; p < 0.01 for 4E-BP1 (4Ala) versus 4E-BP1
wt or vector). These data support the hypothesis that inhibition
of 4E-BP1 function by AKT and ERK signaling is required to
activate translation and maintain the malignant phenotype in
tumors with PI3K and RAS mutation.
DISCUSSION
Human tumors almost invariably harbor mutations in a multitude
of oncogenes and tumor suppressor genes.Mutations that resultCancer Cell 18, 39–51, July 13, 2010 ª2010 Elsevier Inc. 45
Figure 6. Combined Inhibition of AKT and MEK Is Required to Dephosphorylate 4E-BP1 and Suppress Tumor Growth In Vivo
(A) Mice bearing established HCT116 xenografts were treated with PD0325901 (5 mg/kg), AKTi (100 mg/kg), combination of both drugs, or vehicle control once
daily. Tumors were excised at various times after the fourth dose of drug administration. Tumor lysates were immunoblotted with the indicated antibodies.
(B–E) Mice bearing HCT116 (B), T84 (C), DLD-1 (D), and HCT15 (E) xenografts were treated with PD0325901 (5 mg/kg), AKTi (100 mg/kg), combination of both
drugs, or vehicle control once daily for 5 consecutive days each week. The results are presented as the mean tumor volume ± SEM (n = 5 mice/group) from two
independent experiments. See also Figure S5.
Cancer Cell
4E-BP1 Integrates AKT and ERK Functionin activation of the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK
pathways are especially frequent. Moreover, mutations that acti-
vate these two pathways often coexist in certain tumors; thus
RAS and PI3K mutation, BRAF and PI3K mutation, BRAF and
PTEN mutation, and variant EGFR expression and PTEN muta-
tion occur together in colorectal carcinoma, thyroid carcinoma,
melanoma, and glioblastoma, respectively (Liu et al., 2008;
Mellinghoff et al., 2005; Nosho et al., 2008; Simi et al., 2008;
Tsao et al., 2004). Tumors with activation of PI3K/AKT signaling
in the absence of EGFR, RAS, or BRAF mutation tend to be
dependent on the pathway and sensitive to selective inhibition
of AKT (She et al., 2008; Yu et al., 2008). Similarly, tumors with
RAS or RAF mutation tend to be sensitive to MEK inhibition if
PI3K or PTEN are not also mutated (Hoeflich et al., 2009; Solit
et al., 2006; Wee et al., 2009 and Figure S2A). RAS-dependent
tumorigenesis in animal models has been reported to require
PI3K activation by RAS, but the growth of established tumors
with RAS mutation is insensitive to PI3K inhibitors (Engelman
et al., 2008) and, as shown here, to AKT inhibitors.
The usual rationalization for coexistent oncogenic mutations in
components of the signaling apparatus is that they mediate
different aspects of the transformed phenotype that allow for
their coselection. However, in this paper and elsewhere, we
and others have shown that tumors with coexistent mutation of46 Cancer Cell 18, 39–51, July 13, 2010 ª2010 Elsevier Inc.both pathways tend to be insensitive to inhibition of either alone,
but sensitive to their combined inhibition (Engelman et al., 2008;
Hoeflich et al., 2009; She et al., 2005; Wee et al., 2009; Yu et al.,
2008). These results suggest that neither pathway alone sub-
serves a key function or that the original selective advantage of
the first mutation has been lost. In this paper, we provide an
explanation for the loss of dependence of these tumors on either
pathway alone. In tumors sensitive to AKT inhibition, phosphor-
ylation of certain downstream targets such as S6 and 4E-BP1
and cap-dependent translation are dependent on AKT signaling.
In contrast, in tumors with coactivation of both AKT and ERK,
inhibition of either is insufficient to adequately inhibit these
processes; inhibition of both is required. Moreover, deletion of
the oncogenes responsible for activation of either pathway is
sufficient to confer dependence on the other. The results sug-
gest that PI3K/AKT and MEK/ERK signaling converge on a
common set of targets that integrate their function. Activation
of either pathway is sufficient to affect these integrators; thus,
the second mutation eliminates the dependence of both the
target and the tumor cell on either.
AKT and ERK signaling affects many common downstream
targets and processes, including regulators of cell cycle pro-
gression, apoptosis, transcription, and translation (Manning
and Cantley, 2007; McCubrey et al., 2007). In normal cells, these
Figure 7. Activated 4E-BP1 Represses
PI3KCA and KRAS Mutant Tumor Growth
(A) HCT116 cells expressing vector, HA-4E-BP1
wt, or HA-4E-BP1 (4Ala) were immunoblotted
with the indicated antibodies or precipitated with
m7GTP sepharose beads followed by immuno-
blotting of HA, 4E-BP1, and eIF4E.
(B) HCT116 cells expressing vector, HA-4E-BP1
wt, or HA-4E-BP1 (4Ala) were transplanted into
the right flank of nude mice. Tumor volume was
measured twice each week with the results pre-
sented as mean tumor volume ± SEM of five
mice in each group.
(C) Representative tumors expressing vector,
HA-4E-BP1 wt, or HA-4E-BP1 (4Ala), and immu-
noblot analysis of the tumor lysates with indicated
antibodies.
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4E-BP1 Integrates AKT and ERK Functionfunctions are regulated by a complex signaling network, but,
in tumor cells, ‘‘oncogene addiction’’ implies that they have
become dependent on a single, dominant, oncoprotein-acti-
vated pathway. Mutational activation of the second pathway
would then serve to reduce dependency on either. The down-
stream convergence of PI3K/AKT and ERK signaling may
account for the significant frequency of coexistent mutations in
these pathways. The selective advantage for the second muta-
tion is not certain; it may lie in divergent effects of the second
pathway, but it is also possible that the dependence of key
processes such as translation on a single oncogene-activated
pathway may result in decreased fitness of the cell in certain
environments. In support of this possibility, the growth of tumor
xenografts with mutant RAS is slowed in calorie restricted mice
and this effect is rescued by coexistent PIK3CA mutation
(Kalaany and Sabatini, 2009). This interpretation is consistent
with that of Ericson et al. who report that in tumors with coexis-
tent RAS and PI3Kmutations, AKT was required for growth only
in challenging microenvironments, such as growth factor deple-
tion and during the metastatic process (Ericson et al., 2010).
Whatever the mechanism of selection, it is clear that the second
mutation reduces or eliminates the dependency or ‘‘addiction’’
of the tumor to the first mutation. Whether this loss of depen-
dency is responsible for the selection or is a neutral by-product
of the second hit, it has important clinical and biologic
implications.
The data reported here support recent studies that show
that activation of cap-dependent translation plays an important
role in induction and maintenance of the transformed pheno-
type (Mamane et al., 2004; Polunovsky and Bitterman, 2006).
The phosphorylation of two components of the translationCancer Cell 18, 39machinery, S6 and 4E-BP1, was shown
to be dependent on AKT signaling in
tumors in which the PI3K/AKT pathway
is dysregulated, but not in those in which
there is coexistent mutational activation
of ERK signaling. In such tumors, com-
bined inhibition of both pathways is
required to affect their phosphorylation
and to significantly inhibit cap-depen-
dent translation. Thus, these two proteinsare candidate integrators of AKT and ERK signaling that
may play a role in mediating transformation and oncoprotein
dependency.
In particular, 4E-BP1 is identified as a key downstream target
of both mutant PI3K and RAS-activated signaling in human
cancer cells. Knockdown of this inhibitor of translation in tumor
cells markedly reduces their dependence on activated signaling
for translation and survival. This is somewhat surprising, given
that these pathways also activate the phosphorylation of the
S6K, S6 ribosomal protein, and other regulators of translation,
including other members of the 4E-BP family (Pause et al.,
1994). However, in the experiments reported here, knockdown
of either S6K, S6, or 4E-BP2, alone or in combination with
4E-BP1 has more than a marginal effect. This suggests that
4E-BP1 inhibition is responsible for much of the activation of
translation by RAS and PI3K/AKT in these cells and this in turn
plays an important part in mediating the effects of these path-
ways in the tumor. It is consistent with recent clinical findings
that expression of high levels of phosphorylated 4E-BP1 are
associated with poor prognosis in several tumor types, indepen-
dent of specific upstream oncogenic alterations (Armengol et al.,
2007). The AKT dependence of phosphorylation of 4E-BP1 and
of tumor growth is closely correlated. These data suggest that
this relationship is causal. This is supported by our finding that
a dominant negative 4E-BP1 incapable of being phosphorylated
in response to upstream pathways is sufficient to suppress the
growth of HCT116 tumors in vivo. Others have found that the
nonphosphorylated (activated) 4E-BP1 is capable of suppress-
ing tumorigenesis in PTEN mutant breast cancer (Avdulov
et al., 2004) andKRASmutant non-small cell lung cancer (Jacob-
son et al., 2006). We thus show that tumor cells in which both–51, July 13, 2010 ª2010 Elsevier Inc. 47
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sensitive to their combined inhibition or to dominant activated
4E-BP1. Furthermore, tumors in which eIF4E is overexpressed
or 4E-BP1 expression is knocked down lose dependence on
AKT and ERK signaling. Taken together, these data support
the conclusion that inhibition of 4E-BP1 function by activation
of AKT and ERK signaling plays a crucial role in maintaining
the transformed phenotype and add support to the idea that
the eIF4E complex represents a valid and intriguing target for
drug development (Graff et al., 2008).
The mTOR kinase is another downstream target of both AKT
and ERK signaling that integrates their function. This may occur
via phosphorylation of TSC2 and perhaps other proteins by both
pathways (Ma et al., 2005;Manning et al., 2002). ThemTOR-con-
taining TORC1 complex is responsible for phosphorylation of
S6K and 4E-BP1 by the enzyme. Rapamycin is a selective inhib-
itor of the TORC1 complex but is much less effective than com-
bined inhibition of AKT and MEK in downregulating 4E-BP1
phosphorylation and its binding to eIF4E, or inducing apoptosis
in tumor cells with coexistent RAS and PI3Kmutations (data not
shown). This suggests that the effects of AKT andMEK inhibition
aremediated by other targets in addition tomTOR. However, this
result is complicated by the recent report that rapamycin is only
a modest inhibitor of TORC1 activity and that mTOR kinase
inhibitors are much more efficient downregulators of 4E-BP1
phophorylation (Feldman et al., 2009; Thoreen et al., 2009).
However, the TORC2 complex is also an upstream activator
of AKT (Sarbassov et al., 2005) and T70 phosphorylation of
4E-BP1 is sensitive to AKT/MEK inhibition and reported to be
insensitive to mTOR kinase inhibition (Thoreen et al., 2009).
Furthermore, phosphorylation of 4E-BP1 and its activity have
also been shown to be regulated by the PP2A phosphatase
and other kinases independent of mTOR (Herbert et al., 2002;
Imai et al., 2008; Michlewski et al., 2008). Thus, it is still unclear
whether all of the effects of AKT and ERK signaling on 4E-BP1
are integrated by mTOR.
It is likely that someof the effects of combined inhibition of AKT
and ERK aremediated by other targets, including components of
the apoptotic machinery (She et al., 2005). We have previously
shown that BAD is a downstream target that can integrate
EGFR/ERKandPI3K signaling in PTEN-negative/EGFRamplified
tumors and that knocking down BAD significantly (50%) atten-
uates the effects of combined pathway inhibition in MDA-468
breast cancercells (Sheet al., 2005). InHCT116cells, knockdown
of BAD expression reduces induction of apoptosis in response to
combined pathway inhibition by 25% (data not shown). How
activation of cap-dependent translation interacts with regulation
of apoptotic regulators tomediate oncogenic survival signaling is
likely to be complex and a matter for further investigation.
These are important questions because relatively selective
inhibitors of RAF, MEK, PI3K, AKT, and mTOR kinases are now
available and many are in early clinical testing. This work sug-
gests that the tumors from patients in these trials should be
evaluated for mutations in components of both pathways and
tumors with coexistent mutations in both pathways will not
respond to inhibition of one alone. This hypothesis should now
be tested in these clinical trials. Furthermore, dephosphorylation
of 4E-BP1 in response to drug should be an important biomarker
for predicting response to therapy.48 Cancer Cell 18, 39–51, July 13, 2010 ª2010 Elsevier Inc.The tolerability of the combined inhibition of AKT and ERK and
its synergistic effects on cap-dependent translation and on
tumor growth suggest that this strategy might be useful in the
variety of metastatic tumors in which these pathways are coac-
tivated. There is currently no therapeutic agent that directly and
effectively inhibits RAS function. Since RAF and PI3K are two of
the key effectors of the transforming activity of mutant RAS,
the combined inhibition of MEK and AKT may constitute an
anti-RAS therapeutic strategy as well, of potential utility in
diseases (pancreatic, colon, lung carcinoma) with mutated
RAS for which there are few and only marginally effective thera-
pies. Given the importance of 4E-BP1 in integrating the effects
of AKT and ERK on protein translation and apoptosis, mTOR
kinase inhibitors currently in development may also be useful
for treating these tumors. However, these inhibitors release the
feedback inhibition of receptor tyrosine kinases and activate
both ERK and PI3K/AKT in tumors (N. Rosen, unpublished
data and Carracedo et al., 2008). Combined inhibition of ERK
and AKT both effectively inhibits 4E-BP1 phosphorylation and
prevents reactivation of ERK and AKT and thus may have a ther-
apeutic advantage.EXPERIMENTAL PROCEDURES
Cell Culture and Inhibitors
Human tumor cell lines were obtained from the American Type Culture Collec-
tion (ATCC) and maintained in the appropriate medium supplemented with
2 mM glutamine, 50 units/ml each of penicillin and streptomycin, and 10%
FBS as suggested by ATCC. The isogenic cell lines with deletion of mutant
alleles of KRAS (Shirasawa et al., 1993) or PIK3CA (Samuels et al., 2005)
from HCT116 or DLD-1 cells were grown similarly in McCoy’s 5A medium.
The AKTi was obtained from Merck (Bilodeau et al., 2008). The MEK inhibitor
PD0325901 was synthesized as described (Barrett et al., 2008). Both inhibitors
were dissolved in dimethyl sulfoxide.
Cell Viability/Proliferation and Apoptosis Assays
Cells were seeded in 96-well plates at a density of 2000–5000 cells in tripli-
cates. After 24 hr, cells were treated with different concentrations of the indi-
cated kinase inhibitors and incubated at 37C. The cells were cultured for
3 days, and then the number of viable cells was measured by CellTiter-Glo
luminescent cell viability assay (Promega) (She et al., 2008). Cell proliferation
was detected by a chemiluminescent immunoassay based on the measure-
ment of bromodeoxyuridine incorporation during DNA synthesis according
to the manufacturer’s standard protocol (Roche Applied Science). For
in vitro combination studies, the synergy was assessed with the combination
index (CI) of Chou and Talalay method with CompuSyn software (Chou and
Talalay, 1984). Generally, CI values of <1 are taken to indicate synergistic
interaction between drugs, and CI values of >1 indicate no interaction (drug
antagonism). To measure apoptosis, both adherent and floating cells were
harvested after drug treatment, and the cell nuclei were stained with ethidium
bromide (She et al., 2008). Detection and quantitation of apoptotic cells (sub-
G1 fraction) were performed by flow cytometric analysis.
Immunoblot Analysis
Protein extracts were prepared by cell lysis in buffer containing protease and
phosphatase inhibitors, subjected to SDS-PAGE, and analyzed by immuno-
blot using primary antibodies as indicated throughout. Methodological details
are provided in Supplemental Experimental Procedures.
Cap-Binding Assay
Cell lysates as prepared above were incubated with m7 GTP sepharose beads
(GE Healthcare) to capture eIF4E and its binding partners. Precipitates were
washed three times with lysis buffer, resuspended in 23 Laemmli sample
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4E-BP1 Integrates AKT and ERK Functionbuffer, and resolved by SDS-PAGE followed by immunoblot with the indicated
antibodies.
Quantification of Cap-Dependent Translation
Cells (250,000) were transfected with a bicistronic luciferase reporter plasmid
(2 mg), pcDNA3-rLuc-PolioIRES-fLuc, which directs cap-dependent transla-
tion of the Renilla luciferase gene and cap-independent Polio IRES-mediated
translation of the firefly luciferase gene (Pause et al., 1994), in six-well plates
using Lipofectamine 2000 (Invitrogen). After 24 hr transfection, cells were
treated with kinase inhibitors for the indicated times. Cell were rinsed with
PBS and incubated with the passive lysis buffer (Promega) for 15 min. Cell
debris was pelleted by centrifugation, and triplicate supernatant samples
were assayed for Renilla luciferase and firefly luciferase activities in an Analyst
AD (Molecular Devices) using a dual-luciferase reporter assay system (Prom-
ega). Cap-dependentRenilla activity was normalized against cap-independent
firefly activity as the internal control. TheRenilla/firefly luciferase luminescence
ratio was calculated for cap-dependent translational activity (Roux et al.,
2007).
Polysome Analysis
Sucrose density gradient centrifugation was employed to separate the ribo-
some fractions following treatment of cells with drugs. Fifteen minutes before
collection, cycloheximide (100 mg/ml) was added to the culture medium. Cells
were washed in ice-cold PBS containing 100 mg/ml cycloheximide and har-
vested in polysome lysis buffer (5 mM Tris-HCl [pH 7.5] 2.5 mM MgCl2,
1.5 mM KCl, 2 mM DTT, 0.5% Triton X-100, 0.5% sodium deoxycholate,
100 mg/ml cycloheximide, RNAsin inhibitor, protease and phosphatase inhib-
itors). Cells were incubated on ice for 15 min and then centrifuged at 10,000g
for 10 min at 4C. The supernatant (4 mg of protein) was layered on a pre-
chilled 10%–50% linear sucrose gradient preparing in 5 mM Tris-HCl
[pH 7.5], 2.5 mM MgCl2 and 1.5 mM KCl, and then centrifuged in a Beckman
SW40Ti rotor at 35,000 rpm for 2.5 hr at 4C. Gradients were fractionated while
monitoring absorbance at A254 with a Density Gradient Fractionation System
(Teledyne ISCO).
35S-Methionine Incorporation Assay
Cells were labeled with 100 mCi of 35S-methionine per ml (Perkin Elmer) in
methionine-free medium (Invitrogen) for 1 hr, washed twice with PBS, and
lysed in the NP-40 lysis buffer as above. Lysates were clarified by centrifuga-
tion for 10 min at 10,000g. Labeled proteins were precipitated with trichloro-
acetic acid and resuspended in 0.5 N NaOH. The proteins were transferred
to glass microfiber filters (Whatman) and counted in a scintillation counter.
35S-methionine incorporation was normalized to protein amount.
Gene Silencing by siRNA
siRNAs were purchased fromDharmacon. Cells were seeded in six-well plates
at a density of 150,000 cells/well. In the next day, cells were transfected with
20 nM siRNA pool against human KRAS (L-005069), AKT1 (L-003000), AKT2
(L-003001), MNK1 (L-004879), MNK2 (L-004908), 4E-BP1 (L-003005), 4E-BP2
(L-018671), p70S6K1 (L-003616), S6 (L-003024), BAD (L-003870), or nontar-
geting control siRNA pool (D-001810-10) with Lipofectamine RNAiMAX
reagent according to the manufacturer’s instructions (Invitrogen). After 48 hr
transfection, cell were treated with kinase inhibitors for the indicated times
and subjected to immunoblot analysis and assays for cap-dependent transla-
tion and apoptosis.
DNA Constructs, Virus Production, and Infection
Retroviral constructs including MSCV-eIF4E and empty vector MSCV-GFP
(Wendel et al., 2004), pBABE-HA-4E-BP1, pBABE-HA-4E-BP1 (4Ala), and
pBABE empty vector (Rong et al., 2008) were transfected into amphotropic
phoenix 293T packaging cells. After 48 hr, virus-containing medium was
filtered, collected, and used to infect HCT116 cells in the presence of 8 mg/ml
of polybrene (Millipore) for three times at 4 to 5 hr intervals. Cell population
expressing eIF4E were obtained by sorting infected cells according to GFP
intensity at 488 nm laser emission using a Becton Dickinson FACS AriaII (BD
Biosciences) with a 530/30 optical filter, followed by assessment by immuno-
blot. The stable transfectants with expression of HA-4E-BP1 and its mutant(4Ala) were obtained by selection with puromycin (2 mg/ml, Sigma) for
1 week and further analyzed by immunoblot.
Animal Studies
Six-week-old nu/nu athymic female mice (NCI-Frederick Cancer Center) were
maintained in pressurized ventilated cages. Experiments were carried out
under an IACUC approved protocol and institutional guidelines for the proper
and humane use of animals in research were followed. Tumors were generated
by transplanting 1.5 to 3 3 106 tumor cells in a 1:1 mixture of media and
Matrigel (BD Biosciences) into the right flank (200 ml/mouse). Prior to initiation
of treatment, mice were randomized among control and treated groups (n = 5
per group). AKTi was formulated in 25% hydroxypropyl b-cyclodextrin
(pH 4–5), and administered subcutaneously at a dose of 100 mg/kg per day
for 5 consecutive days each week. PD0325901 was formulated in 0.5%
hydroxypropyl methyl-cellulose plus 0.2% Tween 80 and administered orally
at a dose of 5 mg/kg per day for 5 consecutive days each week. For combina-
tion treatment, both drugs were given concurrently. Control mice received
vehicle alone for both drugs. The average tumor diameter (two perpendicular
axes of the tumorweremeasured) wasmeasured in control and treated groups
using a caliper. The data are expressed as the increase or decrease in tumor
volume in mm3 (mm3 = p/6 3 [larger diameter] 3 [smaller diameter]2).
Unpaired, two-tailed Student’s ttest was used to assess statistical signifi-
cance. To prepare lysates, tumor tissue was homogenized in 2% SDS lysis
buffer and then processed for immunoblot.
SUPPLEMENTAL INFORMATION
Supplemental information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.ccr.2010.05.023.
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